ChinaChina Patent OfficeCNIPAFeePCT
6 September 2024

New Fee Standards Released for Chinese Patent Applications

by
Dr. Caleb Liu
Ms. Yolanda Wang

Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE).

Please find our summary below:

PCT application fee deduction rules

 

Application fee & extra fees (claims/pages)

Substantive examination fee

PCT application type

Before

Jul 26, 20242

After

Jul 26, 2024

Before

Jul 26, 2024

After

Jul 26, 2024

CNIPAas RO

CNIPA as ISA or IPEA

100% OFF

100% OFF

100% OFF

100% OFF

non-CN as ISA or IPEA

EPO as ISA


JPO as ISA


SPO as ISA

100% OFF

No discount

20% OFF

No discount

All others as ISA or IPEA

No discount

No discount

No discount

No discount

non-CN as RO

CNIPA as ISA or IPEA

No discount

No discount

100% OFF

100% OFF

non-CN as ISA or IPEA

EPO as ISA


JPO as ISA


SPO as ISA

No discount

No discount

20%OFF

No discount

All others as ISA or IPEA

No discount

No discount

No discount

No discount

  • Abbreviations

    • CNIPA - China National Intellectual Property Administration

    • Non-CN – other patent offices than CNIPA

    • NPE - National Phase Entry

    • IPEA - International Preliminary Examining Authority
  • RO - Receiving Office

  • ISA - International Search Authority

  • EPO - European Patent Office

  • JPO - Japan Patent Office

  • SPO - Swedish Patent Office

Fee standards for PTA/PTE

Under the new fee schedule, the official fee for PTA/PTE requests is CNY 200/patent. If any PTA/PTE request has been filed before July 26, 2024, the PTA/PTE request fee thereof must be paid before October 26, 2024.

If PTA/PTE is granted, the annuity fee during the patent compensation period is CNY 8000/patent/year.

A SPECIAL NOTE: The annuity fee for the patent compensation period must be paid in a lump sum before the expiration of the 20-year patent term. No late payment, restoration, or fee reduction is applicable.

Others

During the implementation period of the patent open license, the annuity fee will be reduced by 15%. If other patent fee reduction policies are also applicable, the most favorable policy can be selected, but only one fee reduction policy may be used per patent.

EIP Thoughts

The new PCT application fee deduction rules are intended to promote CNIPA as the ISA and IPEA for international patent applications.

It has been over four years since PTA/PTE were first introduced in the latest 4th Amendment to the Patent Law. Now we finally have a complete set of procedural requirements for PTA/PTE requests. So far, the procedure has been smooth, and we have already had several requests successfully granted.

We will continue to monitor developments closely and keep you informed of any further updates.

Related Articles

A More Detailed Overview of China’s Patent Term Extension (PTE) System

Everything you need to know about Patent Term Adjustment (PTA) in China

If you would like to have more information on this matter or would like to have our advice, please feel free to contact us at [email protected].

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

    1. Notice on Adjusting and Optimizing Patent Fee Policy, Finance and Taxation [2024] No. 23” and “Notice on the Annual Fee Standard for the Patent Compensation Period and Other Related Matters, Development and Reform Price [2024] No. 1156,” and “Announcement on Adjusting Certain Patent Fee Standards and Reduction Policies (No. 594)” and “Notice on the Payment of Patent Term Compensation Fees and Other Related Matters”.

      ↩︎
    2. Appendix 2 of “Notice of the National Development and Reform Commission and the Ministry of Finance on Reissuing the Administrative and Institutional Fee Standards of the National Intellectual Property Administration and Other Related Issues, Development and Reform Price [2017] No. 270.”

      ↩︎

    Other Articles

    China Releases Draft Implementation Guidelines for the Drug Administration Law

    2 June 2022
    The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

    The Latest on Post-Filing Data in China’s Patent Law

    29 April 2020
    Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]

    Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

    1 April 2025
    “Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]

    Why Do Examiners Fail to Recognize the Importance of my “Parameter Features”?

    28 May 2025
    The Impact of Parameter Features on Inventiveness ”Parameter features” – numerical or mathematical expressions that define the quantity or physical properties of a subject – frequently appear as technical features within a claim. Often described as numerical ranges or measurements, they frequently play a critical role in addressing technical problems. However, in practice, Examiners and […]

    Our Past Events

    Top crossarrow-right